Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2013 1
2014 1
2016 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Activation of innate immunity to reduce lung metastases in breast cancer.
Jordan JL, Nowak A, Lee TD. Jordan JL, et al. Cancer Immunol Immunother. 2010 May;59(5):789-97. doi: 10.1007/s00262-009-0800-x. Epub 2009 Dec 3. Cancer Immunol Immunother. 2010. PMID: 19956948
Breast cancer continues to be one of the leading causes of cancer death in women. ...We found that oral Cs does not reduce primary tumour growth but can reduce lung metastasis occurrence in a surgical excision model of metastatic m
Breast cancer continues to be one of the leading causes of cancer death in women. ...We found that oral Cs does not
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Guerriero JL, et al. Nature. 2017 Mar 16;543(7645):428-432. doi: 10.1038/nature21409. Epub 2017 Mar 8. Nature. 2017. PMID: 28273064
Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. . …
Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatmen …
Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML. Jovanovic IP, et al. Int J Cancer. 2014 Apr 1;134(7):1669-82. doi: 10.1002/ijc.28481. Epub 2013 Oct 10. Int J Cancer. 2014. PMID: 24105680 Free article.
The role of IL-33/ST2 pathway in antitumor immunity is unclear. Using 4T1 breast cancer model we demonstrate time-dependent increase of endogenous IL-33 at both the mRNA and protein levels in primary tumors and metastatic lungs during cancer progressio …
The role of IL-33/ST2 pathway in antitumor immunity is unclear. Using 4T1 breast cancer model we demonstrate time-depen …
PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.
Henkels KM, Muppani NR, Gomez-Cambronero J. Henkels KM, et al. PLoS One. 2016 Nov 16;11(11):e0166553. doi: 10.1371/journal.pone.0166553. eCollection 2016. PLoS One. 2016. PMID: 27851813 Free PMC article.
Phospholipase D-2 (PLD2) has a key role in breast cancer formation and metastasis formation with PLD small inhibitors reducing primary tumor growth. ...This significantly increased ("emboldened") macrophage function was due to PLD inhibition. Since tum …
Phospholipase D-2 (PLD2) has a key role in breast cancer formation and metastasis formation with PLD small inhibitors …
Feedback